Xylem (XYL) Stock Forecast & Price Target

Xylem is supported by resilient underlying demand, with 3Q26 organic orders up 10% and backlog rising to $5.5 billion, suggesting that the recent stock pullback reflects timing delays rather than a structural deterioration in the franchise. Its outlook is strengthened by portfolio simplification and higher-quality growth, including the planned divestiture of roughly $800 million of revenue businesses that are less than 5% of EBITDA and the Jan. 1, 2027 move to three cleaner segments focused on treating, moving, and measuring water. Management’s exposure to datacenters, semiconductor-related treatment wins, and a maturing 80/20 program should enhance margins and growth, while shares trading at a 22% discount to peers versus a historical 0%-40% range leave valuation support for the Outperform view.

Xylem is facing a weaker fundamental setup as 3Q26 revenue missed expectations across three of four segments, organic growth was roughly flat, and management cut full-year 2026 EPS guidance to $5.40-$5.45 from $5.55-$5.70 while lowering organic growth to flat. The softness appears broadening, with M&CS down 5% organically, WSS down 2%, and 4Q26 organic growth guided to (2%)-(1%), reflecting affordability pressure, slower project conversions, and deferred spending amid higher construction, energy, and financing costs. Although backlog rose to $5.5 billion and margins still expanded, the reliance on delayed orders and divestitures totaling about $800 million of revenue underscores a challenged near-term demand profile and limited top-line visibility.